AMD and Diabetic Macular Oedema: Towards a More Human and Personalised Approach
On 25 September 2025, at the invitation of Bayer Laboratories, Dr Florian Baudin from our centre and Dr Matthieu Tonini presented on new challenges in the management of patients with exudative AMD and diabetic macular oedema. The focus was placed on an approach centred on anticipating patient needs and reducing the burden of these chronic treatments.
Understanding the "Therapeutic Burden"
Treatment with intravitreal injections (IVT) has transformed patients’ visual prognosis. Its effectiveness depends on intensive follow-up, which can turn the ‘burden of disease’ into a ‘burden of care’. The result is concerning: in France, nearly half of patients (48.5%) stop treatment in less than a year.
Solutions: Reducing the burden through innovation and communication
- Therapeutic Innovation
- Therapeutic Alliance
- Integrating the Caregiver
The use of next-generation molecules with prolonged duration of action is a priority. They allow for a significant reduction in the frequency of injections, and therefore, the entire logistical and psychological burden associated with them.
Better information and more time dedicated to dialogue are key factors for treatment adherence. It is crucial to explain to the patient that stabilizing vision is already a success and to manage expectations together.
The caregiver is not just a simple companion, but a true partner in care who must be formally integrated into the treatment pathway to ensure continuity and support.
Artificial Intelligence: Anticipating for Better Treatment
A fascinating part of the presentation focused on the role of Artificial Intelligence (AI) as a future partner for the doctor. AI is not intended to replace the ophthalmologist, but to enhance their analytical capabilities.
Thanks to the analysis of thousands of OCT scans, deep learning algorithms can now:
- Detect very early signs of disease recurrence (sometimes invisible to the naked eye) to anticipate treatment.
- Predict the progression of the disease in a given patient, helping the doctor to personalise injection intervals.
- Create a “digital twin” of the patient’s eye to simulate the response to different treatments and choose the most effective one.
The goal is clear: to use the power of AI to make even more informed and proactive decisions, in order to preserve the vision of our patients in the long term.
Concrete cases illustrating our approach
OCT
Scientific References
Loewenstein A et al, Ophthalmol Ther, 2025
Dot C et al, J Clin Med, 2023.
Kodjikian L et al., Réalités Ophtalmol., 2024.
Gale RP et al., Acta Ophthalmol., 2023
Creuzot-Garcher et al, Ophtalmol Sci 2022 et Ophthalmol Ther 2023
Okada M et al, JAMA Ophthalmol, 2021
Talks SJ et al, Ophthalmology Therapy, 2023
Schmidt-Erfurth U et al, Progress in Retinal and Eye Research, 2014
Your ophthalmologist answers your questions during the consultation. For a sudden symptom or sudden loss of vision, seek advice promptly: see the eye emergencies page.